HIGHLIGHTS OF PRESCRIBING INFORMATION …

1 HIGHLIGHTS OF PRESCRIBING INFORMATION Defer vaccination for at least 5 months following blood or plasma These HIGHLIGHTS do not include all the INFORMATION needed to use transfusions, or administration of immune globulins (IG). ( , ). VARIVAX safely and effectively. See full PRESCRIBING INFORMATION Avoid use of salicylates for 6 weeks following administration of for VARIVAX. VARIVAX to children and adolescents. ( , ). VARIVAX ------------------------------ ADVERSE REACTIONS ------------------------------ varicella Virus Vaccine Live Frequently reported ( 10%) adverse reactions in children ages 1 to Suspension for subcutaneous injection 12 years include: Initial Approval: 1995 o fever F ( C) oral: o injection-site complaints: ( ).

2 ----------------------------INDICATIONS AND USAGE ---------------------------- Frequently reported ( 10%) adverse reactions in adolescents and VARIVAX is a vaccine indicated for active immunization for the adults ages 13 years and older include: prevention of varicella in individuals 12 months of age and older. (1) o fever F ( C) oral: ----------------------- DOSAGE AND ADMINISTRATION ----------------------- o injection-site complaints: ( ). Each dose is approximately mL after reconstitution and is Other reported adverse reactions in all age groups include: administered by subcutaneous injection. ( ) o varicella -like rash (injection site).

3 Children (12 months to 12 years of age) o varicella -like rash (generalized) ( ). If a second dose is administered, there should be a minimum interval of 3 months between doses. ( ) To report SUSPECTED ADVERSE REACTIONS, contact Merck Adolescents ( 13 years of age) and Adults Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877- 888-4231 or VAERS at 1-800-822-7967 or Two doses, to be administered a minimum of 4 weeks apart. ( ) -------------------------------DRUG INTERACTIONS---------------------------- --- --------------------- DOSAGE FORMS AND STRENGTHS --------------------- Reye syndrome has been reported in children and adolescents Suspension for injection (approximately dose) supplied as a following the use of salicylates during wild-type varicella infection.

4 Lyophilized vaccine to be reconstituted using the accompanying sterile ( , ). diluent. ( , 3, 16) Passively acquired antibodies from blood, plasma, or immunoglobulin potentially may inhibit the response to varicella -------------------------------CONTRAIND ICATIONS ------------------------------- vaccination. ( , ). History of severe allergic reaction to any component of the vaccine Tuberculin skin testing may be performed before VARIVAX is (including neomycin and gelatin) or to a previous dose of varicella administered or on the same day, or six weeks following vaccine. ( ) vaccination with VARIVAX. ( ). Primary or acquired immunodeficiency states.

5 ( ). ----------------------- USE IN SPECIFIC POPULATIONS ----------------------- Any febrile illness or active infection, including untreated Pregnancy: Do not administer VARIVAX to females who are pregnant. tuberculosis. ( ). Pregnancy should be avoided for 3 months following vaccination with Pregnancy. ( , , 17). VARIVAX. ( , , 17). ----------------------- WARNINGS AND PRECAUTIONS------------------------ Evaluate individuals for immune competence prior to See 17 for PATIENT COUNSELING INFORMATION and administration of VARIVAX if there is a family history of congenital FDA-approved patient labeling. or hereditary immunodeficiency.

6 ( ). Avoid contact with high-risk individuals susceptible to varicella Revised: 02/2017. because of possible transmission of varicella vaccine virus. ( ). FULL PRESCRIBING INFORMATION : CONTENTS* Immune Globulins and Transfusions Tuberculin Skin Testing 1 INDICATIONS AND USAGE 8 USE IN SPECIFIC POPULATIONS. 2 DOSAGE AND ADMINISTRATION Pregnancy Recommended Dose and Schedule Lactation Reconstitution Instructions Pediatric Use 3 DOSAGE FORMS AND STRENGTHS Geriatric Use 4 CONTRAINDICATIONS 11 DESCRIPTION. Severe Allergic Reaction 12 CLINICAL PHARMACOLOGY. Immunosuppression Mechanism of Action Concurrent Illness Pharmacodynamics Pregnancy Duration of Protection 5 WARNINGS AND PRECAUTIONS 14 CLINICAL STUDIES.

7 Management of Allergic Reactions Clinical Efficacy Family History of Immunodeficiency Immunogenicity Use in HIV-Infected Individuals Persistence of Immune Response Risk of Vaccine Virus Transmission Studies with Other Vaccines Immune Globulins and Transfusions 15 REFERENCES. Salicylate Therapy 16 HOW SUPPLIED/STORAGE AND HANDLING. 6 ADVERSE REACTIONS 17 PATIENT COUNSELING INFORMATION . Clinical Trials Experience Post-Marketing Experience *Sections or subsections omitted from the full PRESCRIBING INFORMATION 7 DRUG INTERACTIONS are not listed. Salicylates FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE. VARIVAX is a vaccine indicated for active immunization for the prevention of varicella in individuals 12.

8 Months of age and older. 2 DOSAGE AND ADMINISTRATION. Subcutaneous administration only Recommended Dose and Schedule VARIVAX is administered as an approximately dose by subcutaneous injection into the outer aspect of the upper arm (deltoid region) or the anterolateral thigh. Do not administer this product intravascularly or intramuscularly. Children (12 months to 12 years of age). If a second dose is administered, there should be a minimum interval of 3 months between doses [see Clinical Studies ( )]. Adolescents ( 13 years of age) and Adults Two doses of vaccine, to be administered with a minimum interval of 4 weeks between doses [see Clinical Studies ( )].

9 Reconstitution Instructions When reconstituting the vaccine, use only the sterile diluent supplied with VARIVAX. The sterile diluent does not contain preservatives or other anti-viral substances which might inactivate the vaccine virus. Use a sterile syringe free of preservatives, antiseptics, and detergents for each reconstitution and injection of VARIVAX because these substances may inactivate the vaccine virus. To reconstitute the vaccine, first withdraw the total volume of provided sterile diluent into a syringe. Inject all of the withdrawn diluent into the vial of lyophilized vaccine and gently agitate to mix thoroughly.

10 Withdraw the entire contents into the syringe and inject the total volume (approximately mL) of reconstituted vaccine subcutaneously. VARIVAX, when reconstituted, is a clear, colorless to pale yellow liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use the product if particulates are present or if it appears discolored. To minimize loss of potency, administer VARIVAX immediately after reconstitution. Discard if reconstituted vaccine is not used within 30 minutes. Do not freeze reconstituted vaccine. Do not combine VARIVAX with any other vaccine through reconstitution or mixing.